Thienopyrimidine Ion Channel Modulators for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium channel and calcium channel blockers for pain management have limited efficacy due to side effects such as CNS disturbances, dizziness, nausea, and potentially life-threatening cardiac arrhythmias, highlighting a need for more potent and side-effect-reduced antagonists.
Innovation Solution
Development of compounds that inhibit voltage-gated sodium channels and/or calcium channels, specifically represented by a formula I structure, which can treat various pain conditions and disorders with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current sodium channel and calcium channel blockers are used for pain management, then pain relief is achieved, but side effects such as CNS disturbances, dizziness, nausea, and cardiac arrhythmias occur
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (formula I) that alter the pharmacological parameters of sodium and calcium channel blocking. The structural modifications to the thienopyrimidine core, including variations in substituents R1-R6, ring systems, and linker groups, change the drug's affinity and selectivity for specific ion channels, thereby improving therapeutic efficacy while reducing off-target side effects
Solution Approach 2:
The patent employs composite material principles by creating complex heterocyclic compounds that combine multiple functional moieties within a single molecular structure. The compounds integrate a thienopyrimidine core with various heterocyclic rings (pyrrolidine, piperidine, morpholine, etc.), aromatic groups, and functional substituents to achieve multi-target modulation of ion channels, providing enhanced pain relief with improved safety profiles
2Reliability
If higher potency channel blockers are developed to improve pain management, then efficacy increases, but risk of serious side effects such as cardiac arrhythmias increases
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target particular ion channel subtypes with high selectivity. The molecular structure includes localized functional groups and heterocyclic systems that confer preferential binding to sodium and calcium channels involved in pain transmission, while minimizing interaction with cardiac sodium channels, thereby achieving potent analgesia without cardiac arrhythmia risk
Solution Approach 2:
The patent uses intermediary principles by developing compounds that act as selective modulators between the administered drug and the ion channels. The thienopyrimidine-based compounds serve as intermediaries that can selectively bind to and modulate specific voltage-gated sodium and calcium channels, providing a buffer that allows potent pain relief while filtering out harmful effects on cardiac channels through structural selectivity
Data Source
AI summary
The present invention relates to compounds of formula IA-i useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.